Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Biological perspectives]

J L Pujol1, P Demoly, X Quantin

  • 1Service des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Montpellier.

Revue Des Maladies Respiratoires
|August 5, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential benefit of adjuvant everolimus according to endocrine therapy backbone in the randomized UNIRAD trial.

ESMO open·2025
Same author

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

[Resistance to anti-EGFR through the successive and cumulative acquisition of two new oncogenic addictions: BRAF and ALK].

Revue des maladies respiratoires·2024
Same author

Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.

ESMO open·2024
Same author

Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.

Oncogene·2023
Same author

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.

Oncogene·2023
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Tumor progression in non-small cell lung cancer involves genetic instability and phenotypic changes, leading to metastasis. Understanding these biological shifts is crucial for improving Stage III treatment outcomes.

Area of Science:

  • Oncology
  • Cancer Biology
  • Molecular Pathology

Background:

  • Non-small cell lung cancer (NSCLC) progression is a continuum, with Stage III representing a transitional phase defined by anatomical criteria.
  • Metastatic spread is the primary driver of treatment failure in Stage III NSCLC.
  • Understanding the dynamic schema of tumor progression and metastatic diffusion is essential.

Purpose of the Study:

  • To integrate recent developments in the tumor biology of non-small cell bronchial cancer.
  • To elucidate the dynamic schema of tumor progression and metastatic disease diffusion.
  • To highlight key prognostic factors influencing survival in Stage III NSCLC.

Main Methods:

  • Review and integration of current research on NSCLC tumor biology.

Related Experiment Videos

  • Analysis of the continuum between cancer stages, particularly Stage II and III.
  • Identification and emphasis on prognostic factors related to tumor genetics and phenotype.

    • Main Results:

    • Tumor progression in NSCLC is characterized by genotypic instability and phenotypic diversification.
    • There is no distinct biological disruption between Stage II and Stage III NSCLC.
    • Metastatic microscopic disease is the leading cause of treatment failure in Stage III NSCLC.

    Conclusions:

    • Genotypic instability and phenotypic diversification are key drivers of tumor progression in NSCLC.
    • Alterations in p53 expression, aneuploidy, and cellular adhesion molecules are significant prognostic factors.
    • Tumor diversification towards a metastatic phenotype critically impacts patient survival in Stage III NSCLC.